AFMDQ.US Affimed N.V.

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 13, 2026
Market cap
USD 1.64K
P/E
-
P/B
0.00x
ROE
-352.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2024.

Is AFMDQ.US undervalued?

Graham number

The Graham number of Affimed N.V. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Affimed N.V. fundamental analysis

No fundamental analysis for Affimed N.V. yet.

Affimed N.V. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Affimed N.V.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding in…

Full company profile